6.31 0.00 (0.00%)
After hours: 4:56PM EST
|Bid||6.24 x 1100|
|Ask||7.15 x 4000|
|Day's Range||6.17 - 6.55|
|52 Week Range||6.17 - 21.40|
|Beta (3Y Monthly)||3.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2019 - Mar 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.11|
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates today at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5172457. Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.
Epizyme (EPZM) delivered earnings and revenue surprises of 10.00% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 54 cents. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...
Enrollment in Phase 2 Cohort of Follicular Lymphoma Patients with EZH2 Activating Mutations on Track to be Completed by Year End
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced positive interim data from the fully enrolled epithelioid sarcoma cohort of its ongoing Phase 2 study of its lead candidate tazemetostat, a potent, selective, orally available EZH2 inhibitor. The data were presented by the study’s lead investigator, Mrinal Gounder, M.D., attending physician, Sarcoma Medical Oncology and Early Drug Development Services, Memorial Sloan Kettering Cancer Center, during the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Interim data as of August 21, 2018 from the 62 patients enrolled show that tazemetostat treatment demonstrated clinically meaningful activity for patients with epithelioid sarcoma (ES).
Every investor in Epizyme Inc (NASDAQ:EPZM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...
RA Capital and Longitude Capital bought more shares of a firm developing a treatment for eye diseases. NEA invested more in a firm working on cancer treatments.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany. Tazemetostat is the company’s potent, selective, orally available, first-in-class EZH2 inhibitor. The Phase 2 study ES cohort completed enrollment in 2017 with a total of 62 patients.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of its common stock at a public offering price of $9.00 per share, which includes 1,250,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price less the underwriting discount. The aggregate gross proceeds to Epizyme from the offering, before deducting underwriting discounts and offering expenses, are $86.25 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...
Check out the companies making headlines after the bell: Tempur Sealy International TPX shares jumped more than 8 percent in after-hours trading following reports that competitor Mattress Firm is preparing to file for bankruptcy.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Epizyme.
Shares of Epizyme Inc. shot up 25% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the enrolling of new patients in trials of its treatment for non-Hodgkin lymphoma. The FDA's hold had followed a report of a case of T-cell lymphoblastic lymphoma (T-LBL) in its tazemetostat pediatric study. Epizyme said its response to the FDA included a comprehensive assessment of the risk of secondary malignancies. "The Epizyme team has worked diligently to provide a comprehensive response back to the FDA, and through constructive dialogue, we successfully resolved the partial clinical hold," said Chief Executive Robert Bazemore. "This allows us to turn our full attention to our key priorities: preparing for our first NDA submission for tazemetostat in epithelioid sarcoma and defining our registration path in FL." The stock had tumbled 31% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF had gained 5.6% and the S&P 500 had advanced 6.3%.
Epizyme, Inc. (EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of its Phase 2 non-Hodgkin lymphoma trial. Epizyme’s formal response to the FDA included a comprehensive assessment of the risk of secondary malignancies, including T-cell lymphoblastic lymphoma (T-LBL) potentially associated with tazemetostat, which took into account both published literature and the company’s clinical experience to date.
Epizyme, Inc. , a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor confer
Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.
Epizyme (EPZM) delivered earnings and revenue surprises of 20.75% and 458.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?